Radical Concurrent Chemoradiotherapy for Esophageal Cancer

Introduction to Treatment Approach

The American Society of Clinical Oncology recommends definitive concurrent chemoradiotherapy (CCRT) as the standard treatment for patients with locally advanced esophageal cancer who are medically unfit or unwilling to undergo surgery, with radiation doses of at least 50.4 Gy in 1.8 Gy fractions combined with concurrent platinum-based chemotherapy 1, 2

For patients with squamous cell carcinoma (SCC), definitive CCRT is a strong option due to its high radiosensitivity and excellent response rates, with a recommended definitive treatment strategy of close surveillance and salvage surgery for local tumor persistence or progression 2, 3, 4
Modern definitive CCRT has achieved a 3-year overall survival rate of 47.8% and median OS of 35.9 months in SCC patients 3
Definitive CCRT is specifically recommended for cervically localized tumors where surgery would require laryngectomy 3, 4
For adenocarcinoma patients unable or unwilling to undergo surgery, definitive CCRT is the standard treatment, though adenocarcinoma is generally less radiosensitive than SCC 1, 4

The National Comprehensive Cancer Network recommends radiation doses of 50.4 Gy in 1.8 Gy fractions over approximately 5-6 weeks for the United States standard 1, 5
The European Society for Medical Oncology recommends radiation doses of 50.4-60 Gy in 1.8-2.0 Gy fractions for the European/Japanese standard 1, 5
Standard concurrent chemotherapy options include cisplatin/5-fluorouracil (5-FU), carboplatin/paclitaxel, and oxaliplatin/5-FU 1, 3, 4, 6

Combined chemoradiation is definitively superior to radiotherapy alone for patients unable or unwilling to undergo surgery, representing Level I, Grade A evidence from randomized trials 1, 5, 6

Response assessment should include symptomatic evolution, esophagogram, endoscopy with biopsies, and CT scan 6, 7

Close surveillance is essential to identify local tumor persistence or progression, and salvage esophagectomy for incomplete clinical response has been shown to be safe with survival rates similar to planned preoperative CCRT followed by surgery 3, 4

Radiation dose matters, with doses below 50.4 Gy potentially compromising local control 1, 5
Patient selection is crucial, with definitive CCRT reserved for patients with good performance status who can tolerate intensive combined modality treatment 6
Histology influences outcomes, with SCC demonstrating superior response rates to CCRT compared to adenocarcinoma 2
Local recurrence risk is higher with non-operative strategies following CCRT, necessitating rigorous surveillance protocols 3
Multidisciplinary coordination is essential for optimal patient selection, treatment delivery, and surveillance 4